Yackov Berkun, Hadassah Mnt Scopus Rheumatic diseases in children.

Slides:



Advertisements
Similar presentations
RHEUMATOID ARTHRITIS RA Inson lou. Epidemiology Symptoms signs Labs Diagnosis Treatment.
Advertisements

Rheumatoid Arthritis Systemic chronic inflammatory disease
Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.
Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
Lupus in Pregnancy Darren Farley, MD Clinical Assistant Professor
Spondyloarthropathies John Imboden MD
Hatem Eleishi, MD Rheumatologist STILL’S DISEASE.
Overview of Juvenile Idiopathic Arthritis
Dr. Fahim Khan MBBS,MD,MRCP(UK),FRCPLondon,FRCP Edin, FACP Rheum CONSULTANT RHEUMATOLOGIST Aut Even Hospital, Kilkenny Whitfield Clinic Waterford,The St.
Biologics Therapy in Paediatric Rheumatology Rheumatology study day 2014 Alice Chieng.
Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium.
Rheumatoid Arthritis “An Autoimmune Mystery” Cynthia Anderson.
Juvenile Rheumatoid Arthritis B. Paul Choate, M.D.
Musculoskeletal Health in Europe Juvenile Idiopathic Arthritis.
JIA and Other Rheumatic Diseases in Children
Adult Still’s Disease Grant Paulsen AM Report May 22, 2009.
Diagnosing inflammatory arthritis
Psoriatic Arthritis Maggie Davis Hovda Am report 2/16/2010.
DR.IBTISAM JALI MEDICAL DEMONSTRATOR
The Child With Joint Pain Diagnostic Clues
Rheumatology: OSTEOARTHRITIS RHEUMATOID ARTHRITIS Dr. Meg-angela Christi Amores.
All About Rheumatoid Arthritis
SPONDYLOARTROPATHIES
Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.
New Pharmacologic Treatment Options for Managing Rheumatoid Arthritis Devra Dang, Pharm.D. Department of Pharmacy National Institutes of Health.
Treatment of Rheumatoid Arthritis Then and Now
SPONDYLOARTHROPATHIES Prof. Dr. Şansın Tüzün. Definition A family inflammatory arthritides characterized by involvement of both synovium and entheses.
Kathy Bailey Consultant Paediatric Rheumatologist Coventry and Warwickshire.
Paediatric Rheumatology Phil Riley Consultant Paediatric Rheumatologist Teaching.
Selected causes of joint pain in childhood Infection ]Bacterial osteomyelitis± septic arthritis ] Mycobacterium ] Post viral (rubella, EBV, hepatitis.
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
Brief Overview of the Spondyloarthropathies
JRA is the most frequent chronic arthritis of children. The evidence of its was discovered from remained skeleton from 1000 years ago. It was prescribed.
BOARD REVIEW RHEUMATOLOGY Dennis A. Peacock April 9, 2008.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Juvenile Idiopathic Arthritis (JIA)
March 22,  Most common organism?  Staph Aureus  Presentation?  Acute  Monoarthritis  Erythema  Warmth  Swelling  Intense pain.
AM Report 11/24/09 Amy Auerbach  Peak onset between 20 and 30 years  Form of spondyloarthritis (cause inflammation around site of ligament insertion.
Seronegative Spondyloarthropathies
Rheumatoid Arthritis(RA) Dr. Gehan Mohamed. Learning objectives: At the end of this lecture the student should be able to : understand definition,genetic.
Slow Acting Anti-inflammatory Drugs ). BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSF.
LSU Clinical Pharmacology
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Mixed Connective Tissue Disease
Disease modified Anti-rheumatic drugs ( DMARD)
 Juvenile idiopathic arthritis (JIA) is the most common form of childhood arthritis and one of the more common chronic childhood illnesses. As the term.
Juvenile Rheumatoid Arthritis. ACR criteria Age at onset
Rheumatoid Arthritis Christine Aranyi and Rebecca Boon State university of new york institute of technology Pathophysiolog y Rheumatoid Arthritis (RA)
دکتر نوری ” روماتولوژیست WWWW.arrh.ir آرتریت روماتوئید جوانان.
Juvenile Idiopathic arthritis and infectious arthritis 郭三元 Division of R-I-A TSGH.
Introduction to collagen-vascular diseases. Definition: Rheumatologic (or Rheumatic) Disease: diseases characterized by pain and inflammation in joints.
Identifying Early Inflammatory Arthritis
Juvenile Idiopathic Arthritis
The following diseases are accompanied by changes in the joints:
Psoriatic arthritis (PsA) Clinical features, Diagnosis & Management
Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine .
Juvenile Idiopathic Arthritis
Department of Rheumatology and Connective Tissue Diseases
JUVENILE IDIOPATHIC ARTHRITIS
Enteropathic Arthropathy
Drug Therapy of Rheumatoid Arthritis
PEDIATRIC RHEUMATOLOGY OVERVIEW DR. PREETI NAGNUR MEHTA CONSULTANT RHEUMATOLOGIST SUCHAK HOSPITAL & ELITE HOSPITAL, MALAD QQ PUROHIT HOSPITAL, BORIVALI.
Maggie Davis Hovda, MD 3/22/2010
Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.
Dr Sarah Levy Consultant Rheumatologist CUH
Dr Anne Kinderlerer.
common rheumatologic diagnoses
Presentation transcript:

Yackov Berkun, Hadassah Mnt Scopus Rheumatic diseases in children

Juvenile rheumatic diseases A wide range of conditions Inflammatory, mechanical, behavioral or psychological May present with symptoms localized to the musculoskeletal system MS symptoms common in childhood 15% occasional limb pains 5% chronic MS pain, daily activities Lasting for 3 months or more Berkun, JIA 2

Juvenile rheumatic diseases Juvenile idiopathic Arthritis Vasculitis Kawasaki disease Henoch-Schonlein purpura Autoinflammatory FMF Panniculitis CRMO/SAPHO syndromes PFAPA Connective tissue SLE Juvenile dermatomyositis Inflammatory bowel disease Mixed connective tissue disease Linear scleroderma Progressive systemic sclerosis 3

Mechanical/orthopedic Infection/post-infective Viral rubella, measles, mumps, parvo, hepatitis Reactive arthritis Rheumatic fever Septic arthritis Transient hip synovitis Hematological Idiopathic pain syndromes Other Berkun, JIA 4

Introduction, JIA Most frequent chronic inflammatory disease of childhood One of the more common chronic illnesses of childhood and an important cause of disability First series 1890, George Stil 1897 Group of disorders defined by ILAR criteria 1997 Berkun, JIA 5

Epidemiology All races and geographic areas Prevalence: 0.1-4/1000 Chronic disease /1000 Epilepsy 3 DM 1 CP 1.3 JIA 2 6 Berkun, JIA

Objectives To recognize symptoms and signs of clinical subgroups of JIA To understand laboratory and radiology studies helpful when considering the diagnosis To be familiar with the differential diagnosis To understand the general approaches to treatment 7 Berkun, JIA

JRA American College of Rheumatology Revised Criteria Age of onset < 16 years Arthritis of one or more joints Duration of disease > 6 weeks (EULAR 12) Other conditions which present with arthritis in childhood must be excluded 8 Berkun, JIA

ILAR classification Criteria, Durban 1997 Oligoarthritis persistent extended Systemic Polyarticular RF+ Polyarticular RF- Psoriatic arthritis Enthesitis-related arthritis (ERA) Other Berkun, JIA 9

Oligoarthritis Most common 40-60% of JIA 4 or fewer joints in the first 6 months Insidious onset Age 1-3 years Monoarthritis 50% Large joints Knee 50%, ankle, elbow Asymmetric Systemic symptoms absent Uveitis 30% 10 Berkun, JIA

מפרק נפיחות נוזל, היפרטרופיה, בצקת ללא אודם הגבלה בתנועה כאב לא חד ביטוים בתינוק 11 Berkun, JIA

12 Berkun, JIA

13 Berkun, JIA

14 Berkun, JIA

15 Berkun, JIA

Oligoarthritis, Laboratory CBC, ESR normal ANA 60-80% 16 Berkun, JIA March 2010

30% ANA Asymptomatic 50% at diagnosis Within 5 years Bilateral in 2/3 Loss of vision 10% Uveitis 17 Berkun, JIA

Uveitis- hypopion, synechiae 18 Berkun, JIA

Uveitis, Keratic precipitates 19 Berkun, JIA

Uveitis, compl. Band kerathopathy 20 Berkun, JIA

Uveitis, compl. Synechae 21 Berkun, JIA

Slit lamp exam

Oligoarthritis, outcome March 2010 Berkun, JIA 23

24 Berkun, JIA Oligoarthritis, outcome

ILAR classification Criteria, Durban 1997 Oligoarthritis persistent extended Systemic onset Polyarticular RF+ Polyarticular RF- Psoriatic arthritis Enthesitis-related arthritis (ERA) Other Berkun, JIA 25

Systemic onset JIA 10% of JIA Female 40-50% Prominent systemic symptoms fever, rash, lymphadenopathy, hepatosplenomegaly, pericarditis, pleuritis Arthritis may be absent for months to years Uveitis uncommon 26 Berkun, JIA

Fever 2 weeks 39 0 Quotidian Spikes 1-2/d 27 Berkun, JIA SoJIA, clinical features, fever

Arthritis polyarticular May be absent in 20% Berkun, JIA 28

29 Berkun, JIA Rash

30Berkun, JIA

Rash 31 Berkun, JIA

Koebner 32 Berkun, JIA

33 Berkun, JIA

SoJIA, clinical features, rash Evanescent nonfixed erythematous Trunk חיוורון היקפי מופיעה עם חום Koebner phenomena 34 Berkun, JIA March 2010

SoJIA, clinical features, general Serositis Pericarditis 35 Berkun, JIA

Lymphadenopathy Hepatosplenomegaly Berkun, JIA 36 SoJIA, clinical features, general

Systemic JIA, criteria  Arthritis + fever > 2 wks  Quotidian > 3 days +1 of  evanescent nonfixed erythematous  generalized lymphadenopathy  hepato/ splenomegaly  serositis 37 Berkun, JIA

SoJIA, laboratory WBC  , Hgb , platelets  to   ESR    Ferritin    ANA and RF negative 38 Berkun, JIA

Complications Heart tamponade Malnutrition Osteoporosis Joint deformity Amyloidosis Growth retardation Berkun, JIA39

Macrophage activation syndrome Hemophagocytic lymphohistiocytosis Life-threatening complication, cytokine storm NK cells dysfunction Sustained fever, hepatosplenomegaly, anemia, liver dysfunction, coagulopathy, CNS Early diagnosis Aggressive treatment Berkun, JIA 40

Disease courses Berkun, JIA 41 Persistent polyarthritis (50%) Monocyclic, remission within 2–4 years (40%) Relapsing polycyclic Flares systemic + mild arthritis (10%) Poor outcome Systemic features> 0.5 years, thrombocytosis, polyarthritis incl. hip involvement Mortality (2.8% to 14%)

ILAR classification Criteria, Durban 1997 Oligoarthritis persistent extended Systemic Polyarticular RF- Polyarticular RF+ Psoriatic arthritis Enthesitis-related arthritis (ERA) Other Berkun, JIA 42

Polyarticular, fingers 43 Berkun, JIA

Finger tenosynovitis 44 Berkun, JIA

45

Polyarticular disease, laboratory WBC , Hgb , platelets WNL to  ESR  to   ANA 25% 46 Berkun, JIA

Polyarthritis RF+ 5-10% Age >10 years Symmetric Rheumatoid nodules Vasculitis Lung 47 Berkun, JIA March 2010

48 Berkun, JIA

49 Berkun, JIA

50

51 Berkun, JIA

Micrognatia 52 Berkun, JIA

ILAR classification Criteria, Durban 1997 Oligoarthritis persistent extended Systemic Polyarticular RF- Polyarticular RF+ Psoriatic arthritis Enthesitis-related arthritis (ERA) Other Berkun, JIA 53

Psoriatic arthritis Arthritis and psoriasis Dactylitis sausagelike swelling of finger Nail pitting Onycholysis Family history Anterior uveitis, symptomatic 54 Berkun, JIA

Psoriasis Typical lesion -sharply demarcated erythematous plaque covered by silvery white scales, on elbow Initial eruptions- guttate distribution, often triggered by streptococcal infections Scalp – 50%, beyond terminal hair

Nail pitting 56 Berkun, JIA

Dactylitis 57 Berkun, JIA

58 Berkun, JIA March 2010

Enthesitis related arthritis Enthesitis - inflammation at the insertion of tendons, ligaments, or joint capsules to the bone Arthritis lower limb, hip, intertarsal Male >8y Later SIJ, axial involvement HLA B27 Familial history Anterior uveitis, symptomatic 59 Berkun, JIA

60 Berkun, JIA

XR לשלול טראומה, תהליך אחר הרחבת המרווח דלדול עצם כיב בעצם תת סחוסית איבוד סחוס -הצרות sacroiliitis 61 Berkun, JIA

Tecnecium scan 62 Berkun, JIA

Treatment Nonsteroidal anti-inflammatory (NSAIDs) Berkun, JIA63

Treatment, Corticosteroids Uncontrolled or life-threatening SoJIA Local – uveitis, Intra-articularlar Berkun, JIA

Treatment, Methotrexate Most widely used DMARD Mostly in polyarticular disease Oral, IM or SC Adverse events/monitoring stomatitis, leukopenia, nausea/ abdominal pain, anorexia, malaise, fatigue, elevated hepatic enzymes, lung Sulphasalazine Berkun, JIA

Choy EH. N Engl J Med. 2001;344:907–916. Inhibition of Cytokines Activation of anti-inflammatory pathways Anti- inflammatory cytokine Suppression of inflammatory cytokines Neutralization of cytokines Soluble receptor Monoclonal antibody No signal Receptor blockade Monoclonal antibody Receptor antagonist No signal Inflammatory cytokine Normal interaction Cytokine receptor Inflammatory signal

Biologicals Berkun, JIA 67 Anti TNF Etanercept – Enbrel Infliximab – Remicade Adalimumab – Humira Anti-IL-1; anakinra Anti-IL-6 (tocilizumab) T cell co-stimulation inhibitor abatacept

68 Berkun, JIA

69 Berkun, JIA Orencia

Rilonacept (IL-1 receptor) Canakinumab. Anakinra- IL-1 receptor antagonist Berkun, JIA 70

Treatment, splint 71 Berkun, JIA